Karyopharm Net Interest Income from 2010 to 2026
| KPTI Stock | USD 9.41 0.06 0.64% |
Net Interest Income | First Reported 2019-03-31 | Previous Quarter -10.6 M | Current Value -10.5 M | Quarterly Volatility 2.7 M |
Check Karyopharm Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Karyopharm Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 586.2 K, Interest Expense of 48.1 M or Selling General Administrative of 71.8 M, as well as many indicators such as Price To Sales Ratio of 0.52, Dividend Yield of 0.0 or Days Sales Outstanding of 53.98. Karyopharm financial statements analysis is a perfect complement when working with Karyopharm Therapeutics Valuation or Volatility modules.
Karyopharm | Net Interest Income | Build AI portfolio with Karyopharm Stock |
The Net Interest Income trend for Karyopharm Therapeutics offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether Karyopharm Therapeutics is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest Karyopharm Therapeutics' Net Interest Income Growth Pattern
Below is the plot of the Net Interest Income of Karyopharm Therapeutics over the last few years. It is the difference between the revenue generated from a bank's interest-bearing assets and the expenses associated with paying its interest-bearing liabilities. Karyopharm Therapeutics' Net Interest Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Karyopharm Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Interest Income | 10 Years Trend |
|
Net Interest Income |
| Timeline |
Karyopharm Net Interest Income Regression Statistics
| Arithmetic Mean | (9,816,389) | |
| Geometric Mean | 4,937,073 | |
| Coefficient Of Variation | (132.69) | |
| Mean Deviation | 11,831,588 | |
| Median | 1,284,000 | |
| Standard Deviation | 13,025,563 | |
| Sample Variance | 169.7T | |
| Range | 31.7M | |
| R-Value | (0.87) | |
| Mean Square Error | 43.9T | |
| R-Squared | 0.76 | |
| Slope | (2,244,557) | |
| Total Sum of Squares | 2714.6T |
Karyopharm Net Interest Income History
About Karyopharm Therapeutics Financial Statements
Investors use fundamental indicators, such as Karyopharm Therapeutics' Net Interest Income, to determine how well the company is positioned to perform in the future. Although Karyopharm Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
| Last Reported | Projected for Next Year | ||
| Net Interest Income | -27 M | -25.7 M |
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out the analysis of Karyopharm Therapeutics Correlation against competitors. For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is there potential for Biotechnology market expansion? Will Karyopharm introduce new products? Factors like these will boost the valuation of Karyopharm Therapeutics. Expected growth trajectory for Karyopharm significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (16.67) | Revenue Per Share | Quarterly Revenue Growth 0.116 | Return On Assets | Return On Equity |
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Understanding that Karyopharm Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Karyopharm Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Karyopharm Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.